Table 2.
Data from Studies Regarding the Association of Pretherapeutic ADC Values with PFS in PCNSL Patients
| Study (Year) | Regio | Study Design | Patients | Methods of ADC used | ADC Cut-off values used (10-6 mm2/s) | PFS (Low ADC group vs high ADC group) | Hazard Ratio (HR) | 95%CI | p-value |
|---|---|---|---|---|---|---|---|---|---|
| Barajas et al. (2010) | United States | Cohort | 18 | ADC25% | 692 | Mean PFS 9.4 months vs 30 months; p = <0.01 | 0.21 (multivariate analysis) | 0.05 - 0.86 | 0.03 |
| ADCmin | 384 | 0.08 (multivariate analysis) | 0.01 - 0.55 | 0.01 | |||||
| Valles et al. (2013) | United States | Cohort | 25 | ADCmin | 384 | Mean PFS 13.8 months vs 38.9 months; p = 0.04 | 0.24 (multivariate analysis) | 0.08 - 0.71 | <0.01 |
| Zhang, et al. (2020) | China | Cohort | 28 | ADCmean | 800 | Median PFS 5 months vs 12 months; p = 0.009 | 0.465 (multivariate analysis) | 0.17 - 1.22 | 0.121 |
| ADC5% | 500 | Median PFS 4 months vs 15 months; p = 0.001 | 0.086 (multivariate analysis) | 0.012 - 0.615 | 0.014 |